Contrasting Bone Biologics (NASDAQ:BBLG) & NanoVibronix (NASDAQ:NAOV)

Bone Biologics (NASDAQ:BBLG) and NanoVibronix (NASDAQ:NAOV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Bone Biologics and NanoVibronix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	0	0	0	0	N/A
NanoVibronix	0	0	0	0	N/A

Profitability

This table compares Bone Biologics and NanoVibronix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-154.18%	-130.06%
NanoVibronix	-83.49%	-74.98%	-43.38%

Valuation and Earnings

This table compares Bone Biologics and NanoVibronix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$8.95 million	N/A	N/A
NanoVibronix	$2.28 million	0.71	-$3.71 million	($1.29)	-0.45

NanoVibronix has higher revenue and earnings than Bone Biologics.

Insider & Institutional Ownership

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 16.4% of NanoVibronix shares are held by institutional investors. 7.5% of Bone Biologics shares are held by company insiders. Comparatively, 3.6% of NanoVibronix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Bone Biologics has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, NanoVibronix has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.

Summary

NanoVibronix beats Bone Biologics on 5 of the 8 factors compared between the two stocks.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

About NanoVibronix

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.